shutterstock_254160583

Taiho invests in Arcus Biosciences as part of $70 million deal

pharmafile | September 6, 2016 | News story | Manufacturing and Production, Sales and Marketing Arcus, investment, taiho 

Taiho Ventures has invested in California-based Arcus Biosciences alongside GV, Invus, DROIA Oncology Ventures and Stanford University as part of a $70 million series B investment round.

Series A investors include The Column Group, Foresite Capital, Novartis and Celgene.

The funding enables Arcus to continue its rapid drug development activities for the company’s small molecule and antibody immuno-oncology approaches with the goal of building its own internal combinations.

“Taiho Ventures is pleased to support the Arcus team and its promising drug pipeline programmes,’ said Nobuyuki Hashimoto, executive director, board member and global chief corporate officer at Taiho Pharmaceutical.

“Terry Rosen, chief executive officer, and Juan Jaen, president, are among the leaders in the oncology drug discovery field with more than 20 years of experience, and have built an innovative immuno-oncology programme at Flexus, leading to the significant acquisition transaction with Bristol-Myers Squibb in a short period of time,” he continued. “Together, they have many years of industry experience as successful entrepreneurs and are invaluable as they take Arcus to the next level with this significant round of financing.

“The addition of Taiho Ventures to this round of investment will augment the financial and business resources available to Arcus to help build a successful company in the immuno-oncology space, in particular, looking at the Japan and Asian market. They have significant experience in the industry and will provide guidance in the company’s Japan/Asian strategic direction.”

Matt Fellows

Related Content

Abenza announces investment in bioconjugation and ADC capabilities

Abenza has announced a major investment in bioconjugation and antibody drug conjugate (ADC) capabilities in …

Upperton Pharma Solutions announces £5m investment into sterile drug manufacturing

UK-based contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions has announced a £5m investment …

DelSiTech announces closing of €10m financing round for silica-based drug delivery platform

DelSiTech has announced the successful completion of a €10m financing round, marking the largest single …

Latest content